Resolution Therapeutics, a cutting-edge biopharmaceutical company based in Edinburgh, has recently made strategic additions to its leadership team, appointing Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The company is dedicated to pioneering revolutionary regenerative macrophage therapies aimed at treating inflammatory and fibrotic diseases.
In a bold move towards advancing patient care, Resolution Therapeutics recently achieved a significant milestone by successfully dosing the first patient with RTX001, its flagship product. Amir Hefni, the CEO, expressed his excitement about the company’s trajectory and the pivotal role that Singah and Kennedy will play in driving their vision forward.
Lucy Singah brings over two decades of corporate finance expertise to her new role, having worked with both UK and US start-ups as well as global corporations. Her most recent position was as the Chief Financial Officer at Echopoint Medical, following an impressive 11-year tenure at GSK, where she excelled in investor relations, financial leadership, and procurement. Singah’s wealth of experience positions her as a valuable asset in steering Resolution Therapeutics towards financial success and ensuring the progress of RTX001 through clinical trials.
Daniel Kennedy, the newly appointed Chief Business Officer, boasts a robust background in business development spanning more than 20 years. Prior to joining Resolution Therapeutics, Kennedy served as the Vice President for Business Development at Immunocore and played a key role in business development at Achillion Pharmaceuticals before its acquisition by Alexion. His expertise in driving strategic partnerships and fostering growth aligns perfectly with the company’s mission to revolutionize regenerative macrophage therapy.
In a significant financial milestone, Resolution Therapeutics secured £63.5 million in Series B funding last October, with Syncona leading the investment round. This capital injection has been pivotal in advancing RTX001, an autologous pro-regenerative macrophage cell therapy tailored to benefit patients with end-stage liver disease. The company’s flagship clinical trial, EMERALD, is currently underway in the UK and Spain, marking a critical phase in bringing this innovative therapy to those in need.
Expanding its horizons beyond liver disease, Resolution Therapeutics has broadened its manufacturing capabilities and research pipeline to address other inflammatory and fibrotic conditions such as graft-vs-host disease and lung fibrosis. This strategic diversification underscores the company’s commitment to exploring the full potential of regenerative macrophage therapies across a spectrum of challenging medical conditions.
The collaboration between Syncona and the University of Edinburgh Centre for Regenerative Medicine in 2018 laid the groundwork for Resolution Therapeutics’ technological advancements. This partnership has been instrumental in propelling the company’s innovative approach to regenerative medicine, setting the stage for groundbreaking solutions in the field of macrophage therapy.
With a strong focus on research and development, Resolution Therapeutics is poised to revolutionize the landscape of regenerative medicine, offering hope to patients grappling with complex inflammatory and fibrotic disorders. The recent additions to the leadership team signal a new chapter of growth and innovation for the company, as it continues to push boundaries and redefine the future of healthcare.
Don’t miss the latest updates from Resolution Therapeutics and the world of regenerative medicine – subscribe to our newsletter for exclusive insights and industry news.
Key Takeaways:
- Resolution Therapeutics welcomes Lucy Singah and Daniel Kennedy to its leadership team, enhancing its expertise in finance and business development.
- The company’s flagship product, RTX001, marks a significant milestone with the successful dosing of the first patient, paving the way for transformative regenerative macrophage therapy.
- A recent Series B funding round of £63.5 million, led by Syncona, accelerates the development of RTX001 and expands Resolution Therapeutics’ research into diverse inflammatory and fibrotic conditions.
- The collaboration between Syncona and the University of Edinburgh Centre for Regenerative Medicine underscores Resolution Therapeutics’ commitment to innovation and cutting-edge regenerative medicine solutions.
Tags: regenerative medicine, cell therapy
Read more on uk.finance.yahoo.com